Nuclear maspin expression as a good prognostic factor in human epithelial ovarian carcinoma

• Autorzy: Sopel M. , Surowiak P. , Berdowska I.
• Języki publikacji: EN

Abstrakty

EN

Maspin, a protein belonging to the serpin superfamily, seems to exert tumour- -suppressive activity. Its significance in ovarian cancer prognosis is currently under investigation. In the present work, immunocytochemical maspin expression in 132 invasive epithelial ovarian carcinomas was assessed independently in the nucleus and cytoplasm, in correlation with histopathological and clinical data. Positive maspin expression was found in 117 cases: nuclear/cytoplasmatic in 71, exclusive nuclear in 29, and only cytoplasmatic in 17 cases. Cytoplasmatic maspin expression was positively correlated with tumour grade (p = 0.000), FIGO stage (p = 0.002), and distant metastases (p = 0.000) but exhibited no significant correlation with tumour type (p = 0.078). Nuclear maspin expression showed negative correlation with tumour grade (p = 0.025), FIGO stage (p = 0.05), distant metastases (p = 0.001), and cancer remission (p = 0.000) but showed no significant relationship with the patients’ age (p = 0.948) or cancer subtype (p = 0.261). Kaplan-Meier survival analysis showed that strong cytoplasmatic maspin expression was correlated with shorter disease-free survival (p = 0.000) whereas strong nuclear expression was correlated with longer survival (p = 0.000). In Cox regression analysis, low nuclear maspin expression (score 2 and 3) remained a significant independent prognostic factor (p = 0.001) with a relative death risk of 5.337. The obtained results suggest that maspin expression may be a significant marker in epithelial ovarian carcinoma prognosis with its nuclear expression being a good prognostic factor. (Folia Morphol 2010; 69, 4: 204–212)

Słowa kluczowe

EN

maspin; protein expression; immunohistochemistry; prognostic factor; man; epithelial ovarian cancer; woman; human disease

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2010
• Tom: 69
• Numer: 4
• Opis fizyczny: p.204-212,fig.,ref.

Twórcy

autor

Sopel M.

• Department of Pharmaceutical Biology and Botany, Wroclaw Medical University, Al.Jana Kochanowskiego 10, 51-361 Wroclaw, Poland

autor

Surowiak P.

• Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland

autor

Berdowska I.

• Department of Medical Biochemistry, Wroclaw Medical University, Wroclaw, Poland

Bibliografia

• 1. Bailey CM, Khalkhali-Ellis Z, Kondo S, Margaryan NV, Seftor RE, Wheaton WW, Amir S, Pins MR, Schutte BC, Hendrix MJ (2005) Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. J Biol Chem, 280: 34210–34217.
• 2. Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ (2006) Biological functions of maspin. J Cell Physiol, 209: 617–624.
• 3. Bandyopadhyay D, Mishra A, Medrano EE (2004) Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res, 64: 7706–7710.
• 4. Bass R, Fernandez AM, Ellis V (2002) Maspin inhibits cell migration in the absence of protease inhibitory activity. J Biol Chem, 277: 46845–46848.
• 5. Bettstetter M WM, Wild PJ, Rummele P, Blaszyk H, Hartmann A, Hofstadter F, Dietmaier W (2005) Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol, 205: 606–614.
• 6. Biliran H Jr., Sheng S (2001) Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res, 61: 8676–8682.
• 7. Blandamura S, Giacomelli L, Leo G, Segato P, Ninfo V (2006) Nuclear maspin detection in renal cell tumours: possible diagnostic role and correlation with p53 status. Histopathology, 49: 274–282.
• 8. Frey A, Soubani AO, Adam AK, Sheng S, Pass HI, Lonardo F (2009) Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. Histopathology, 54: 590–597.
• 9. Hirai K, Koizumi K, Haraguchi S, Hirata T, Mikami I, Fukushima M, Yamagishi S, Kawashima T, Okada D, Shimizu K (2005) Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Ann Thorac Surg, 79: 248–253.
• 10. Hojo T, Akiyama Y, Nagasaki K, Maruyama K, Kikuchi K, Ikeda T, Kitajima M, Yamaguchi K (2001) Association of maspin expression with the malignancy grade and tumor vascularization in breast cancer tissues. Cancer Lett, 171: 103–110.
• 11. Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S (2002) Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene, 21: 4089–4098.
• 12. Khalkhali-Ellis Z (2006) Maspin: the new frontier. Clin Cancer Res, 12: 7279–7283.
• 13. Kim S, Han J, Kim J, Park C (2004) Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression. Cancer Res, 64: 6900–6905.
• 14. Liu J, Yin S, Reddy N, Spencer C, Sheng S (2004) Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res, 64: 1703–1711.
• 15. Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass HI, Sheng S (2006) Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer, 51: 31–39.
• 16. Maass N, Hojo T, Ueding M, Luttges J, Kloppel G, Jonat W, Nagasaki K (2001) Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res, 7: 812–817.
• 17. Maass N, Teffner M, Rosel F, Pawaresch R, Jonat W, Nagasaki K, Rudolph P (2001) Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. J Pathol, 195: 321–326.
• 18. Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, Kollmannsberger C, Hartmann J, Knuchel R, Kondo M, Jonas U (2001) Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer, 95: 337–342.
• 19. Marioni G, Blandamura S, Giacomelli L, Calgaro N, Segato P, Leo G, Fischetto D, Staffieri A, de Filippis C (2005) Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology, 46: 576–582.
• 20. Mohsin SK, Zhang M, Clark GM, Craig Allred D (2003) Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol, 199: 432–435.
• 21. Oh YL, Song SY, Ahn G (2002) Expression of maspin in pancreatic neoplasms: application of maspin immunohistochemistry to the differential diagnosis. Appl Immunohistochem Mol Morphol, 10: 62–66.
• 22. Pemberton PA, Tipton AR, Pavloff N, Smith J, Erickson JR, Mouchabeck ZM, Kiefer MC (1997) Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. J Histochem Cytochem, 45: 1697–1706.
• 23. Reports based on data of National Cancer Registry: http://85.128.14.124/krn/english/index.asp.
• 24. Rose SL, Fitzgerald MP, White NO, Hitchler MJ, Futscher BW, De Geest K, Domann FE (2006) Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecol Oncol, 102: 319–324.
• 25. Secord AA, Lee PS, Darcy KM, Havrilesky LJ, Grace LA, Marks JR, Berchuck A (2006) Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecol Oncol, 101: 390–397.
• 26. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG (1998) Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer, 82: 893–901.
• 27. Smith SL, Watson SG, Ratschiller D, Gugger M, Betticher DC, Heighway J (2003) Maspin-the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer — is strongly expressed in preneoplastic bronchial lesions. Oncogene, 22: 8677–8687.
• 28. Sobin LH, Fleming ID (1997) TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer, 80: 1803–1804.
• 29. Solomon LA, Munkarah AR, Schimp VL, Arabi MH, Morris RT, Nassar H, Ali-Fehmi R (2006) Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol, 101: 385–389.
• 30. Son HJ, Sohn TS, Song SY, Lee JH, Rhee JC (2002) Maspin expression in human gastric adenocarcinoma. Pathol Int, 52: 508–513.
• 31. Song SY, Lee SK, Kim DH, Son HJ, Kim HJ, Lim YJ, Lee WY, Chun HK, Rhee JC (2002) Expression of maspin in colon cancers: its relationship with p53 expression and microvessel density. Dig Dis Sci, 47: 1831–1835.
• 32. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ (2002) The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res, 8: 2924–2932.
• 33. Umekita Y, Ohi Y, Sagara Y, Yoshida H (2002) Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer, 100: 452–455.
• 34. Umekita Y, Yoshida H (2003) Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology, 42: 541–545.
• 35. Zhang M (2004) Multiple functions of maspin in tumor progression and mouse development. Front Biosci, 9: 2218–2226.
• 36. Zhang M, Volpert O, Shi YH, Bouck N (2000) Maspin is an angiogenesis inhibitor. Nat Med, 6: 196–199.
• 37. Zhang W, Shi HY, Zhang M (2005) Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer, 5: 50.
• 38. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E, Sager R (1994) Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science, 263: 526–529.
• 39. Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, Srivastava S (2000) p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem, 275: 6051–6054.